Skip to content
Search

Latest Stories

Population Health is ‘driving force’ behind Integrated Care Systems, says GP Davies

The voluntary sector and population health management (PHM) are key building blocks of Integrated Care System (ICS) Design Framework, Dr Helen Davies writes in a blog on the NHS.

Davies, who is a GP clinical lead for community and population health management at Calderdale Clinical Commissioning Group, said that earlier many barriers prevented us from truly embedding PHM approaches and opportunities.


However, with the integrated care systems, the forthcoming legislation and incentives for Primary Care falling into line, there is hope for it to become the driving force behind the NHS.

She wrote: “In Calderdale – a place within West Yorkshire and Harrogate (WYH) ICS – we’ve already rolled out PHM techniques to surgeries in every primary care network in the system and are really starting to see the benefits for specific groups of people like those who are homeless, people with diabetes and those living with frailty.

“... we’ve started to think more keenly about our opportunities for reducing health inequalities and offer new and more personalised interventions for at risk groups, whilst working closely with WYH’s own improving population health programme.”

The approach has helped in bringing together health and care professionals from across the integrated care system to look at data in a new way and to identify population groups and assess needs differently.

Davies highlighted three key learning points which other systems starting out might use.

“Firstly, what is the level of maturity, capability and understanding in your system at the start so you can begin with the right strategy to embed PHM? How far have we got in joining up data, have we got a strong population health analytical platform which allows for population and risk grouping, have we got clear leadership and governance to enable PHM approaches? Making sure you have the right organisations and skills (ie analytical) round the table to create the insights you need to guide design is crucial.

“Secondly, taking the time to honestly reflect on what the existing relationships are like in your system. This has been so key to our success that it must be first and foremost of any plan. Again, we had quite a good starting position so expected a bit more from our partners.

“Thirdly, how do we increase true understanding of the problems? Quantitative techniques for creating meaningful insights from the data are critical here but equally important is narrative data – qualitative approaches to tap into local wisdom of patients, carers and providers so we can both bring their insight into where to focus but also involve key groups in care model design.”

She noted that Calderdale has adopted a very person-centred approach to PHM. To substantiate this, she shared the experience of working with the homeless community. As a first step, all the organisations that provide care for the homeless were made to share their views.

This process revealed the need of tightening up the validity of the data – the official numbers were small compared to how many we knew were homeless or leading street-based lives.

After collecting qualitative information, the next step was number crunching from colleagues from across Primary Care, data analysis, voluntary sector and the local councils.

All the data combined with the peoples’ stories helped in developing deep understanding of the cohort. The team is now thinking of ways to ensure better care driven by better data and evidence for these marginalised population groups.

She added that Covid-19 has given a fantastic opportunity to refocus on the specific needs of different communities and groups of people.

“Hopefully the learning from our journey in Calderdale will inspire your system. My expectation is that population health management will continue to drive the agenda of the NHS and its partners, which will benefit the effectiveness and efficiency of the system and improve the care of patients,” Davies wrote.

Meanwhile, commenting on the recently published interim guidance on the functions and governance of the integrated care board, Lou Patten, chief executive of NHS Clinical Commissioners and ICS Network leader at the NHS Confederation, said: “The NHS Confederation, including NHS Clinical Commissioners and NHS Employers, has been heavily involved in partnerships with NHS England and NHS Improvement and trade unions via the Social Partnership Forum to develop this new HR technical guidance.

"We are very grateful for the considerable input of members, and while mindful that central guidance addressing the needs of every system is very difficult to achieve, this has been a really good collaborative effort that seeks to bring clarity as to the way forward.

“Many senior commissioning leaders face uncertainty themselves regarding their futures, but they are committed to ensuring the effective transfer of staff, teams and functions to their new ICS based roles.”

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less